The past, present and future of renin-angiotensin aldosterone system inhibition.

Journal Article (Journal Article;Review)

The renin-angiotensin aldosterone system (RAAS) is central to the pathogenesis of cardiovascular disease. RAAS inhibition can reduce blood pressure, prevent target organ damage in hypertension and diabetes, and improve outcomes in patients with heart failure and/or myocardial infarction. This review presents the history of RAAS inhibition including a summary of key heart failure, myocardial infarction, hypertension and atrial fibrillation trials. Recent developments in RAAS inhibition are discussed including implementation and optimization of current drug therapies. Finally, ongoing clinical trials, opportunities for future trials and issues related to the barriers and approvability of novel RAAS inhibitors are highlighted.

Full Text

Duke Authors

Cited Authors

  • Mentz, RJ; Bakris, GL; Waeber, B; McMurray, JJV; Gheorghiade, M; Ruilope, LM; Maggioni, AP; Swedberg, K; Piña, IL; Fiuzat, M; O'Connor, CM; Zannad, F; Pitt, B

Published Date

  • September 1, 2013

Published In

Volume / Issue

  • 167 / 5

Start / End Page

  • 1677 - 1687

PubMed ID

  • 23121914

Pubmed Central ID

  • PMC4145865

Electronic International Standard Serial Number (EISSN)

  • 1874-1754

Digital Object Identifier (DOI)

  • 10.1016/j.ijcard.2012.10.007


  • eng

Conference Location

  • Netherlands